Giant cell arteritis
1Arthritis & Osteoporosis Center of Reading, 2760 Century Blvd, Wyomissing, Pennsylvania, USA.
Insights
Giant cell arteritis (GCA), a large vessel vasculitis, primarily affects those over 50. While glucocorticoids are standard, agents like Tocilizumab offer steroid-sparing benefits.
Area of Science:
- Rheumatology
- Vascular Medicine
Background:
- Giant cell arteritis (GCA), or temporal arteritis, is a systemic rheumatic disease affecting large and medium-sized vessels, including cranial and great vessels.
- It is the most common idiopathic systemic vasculitis, predominantly seen in individuals over 50 years of age.
- GCA can manifest with systemic symptoms and cranial involvement, leading to characteristic symptoms, or as a generalized disease affecting the aorta and its branches, potentially causing aneurysms and stenosis.
Purpose of the Study:
- To provide a comprehensive review of Giant Cell Arteritis (GCA).
- To cover epidemiology, pathogenesis, clinical manifestations, diagnostic workup, and treatment options for GCA.
Main Methods:
- Literature review of epidemiology, pathogenesis, clinical manifestations, workup, and treatment of GCA.
- Analysis of current treatment strategies, including established glucocorticoid therapy and newer steroid-sparing agents.
Main Results:
- GCA is the most common idiopathic systemic vasculitis, primarily affecting adults over 50.
- Glucocorticoids remain a primary treatment, with agents like Tocilizumab demonstrating efficacy as steroid-sparing options.
- The disease course and treatment duration for GCA are variable.
Conclusions:
- GCA is a significant vasculitic condition requiring a thorough understanding of its diverse presentations and management.
- Effective management involves a combination of established and novel therapeutic approaches to mitigate disease activity and reduce steroid dependence.
- Further research into pathogenesis and treatment optimization is crucial for improving patient outcomes in GCA.
Abstract:
Giant cell arteritis (GCA, also known as temporal arteritis) is classified as a vasculitis of large and medium sized vessels and can involve the cranial vessels as well as the aorta and great vessels. It is a systemic rheumatic disease that virtually never occurs in adults younger than 50 years of age. GCA is the most common idiopathic systemic vasculitis. Systemic symptoms are common and involvement of the muscular, extracranial branches off of the carotid arteries are what result in the classic manifestations of cranial GCA. The disease can also be generalized involving the aorta and its branches leading to aneurysms and stenosis of involved vessels. Glucocorticoids have been the longstanding treatment option for GCA but relatively recent studies have proven additional agents like Tocilizumab are effective steroid sparing agents. GCA is a disease that is of variable duration and length of treatment differs from patient to patient. This article will review the epidemiology, pathogenesis, clinical manifestations, work up and treatment options for GCA.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:23Rheumatic Heart Disease I: Introduction
01:17Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...